- Home
- COLL vs NMM Comparison
COLL vs NMM Comparison
Compare COLL & NMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- NMM
- Stock Information
- Founded
- COLL 2002
- NMM 2007
- Country
- COLL United States
- NMM Greece
- Employees
- COLL N/A
- NMM N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- NMM Marine Transportation
- Sector
- COLL Health Care
- NMM Consumer Discretionary
- Exchange
- COLL Nasdaq
- NMM Nasdaq
- Market Cap
- COLL 958.8M
- NMM 959.8M
- IPO Year
- COLL 2015
- NMM 2007
- Fundamental
- Price
- COLL $30.13
- NMM $37.53
- Analyst Decision
- COLL Strong Buy
- NMM Strong Buy
- Analyst Count
- COLL 4
- NMM 1
- Target Price
- COLL $43.75
- NMM $80.00
- AVG Volume (30 Days)
- COLL 287.8K
- NMM 95.9K
- Earning Date
- COLL 08-07-2025
- NMM 08-19-2025
- Dividend Yield
- COLL N/A
- NMM 0.53%
- EPS Growth
- COLL N/A
- NMM N/A
- EPS
- COLL 1.25
- NMM 11.16
- Revenue
- COLL $664,283,000.00
- NMM $1,319,623,000.00
- Revenue This Year
- COLL $20.04
- NMM N/A
- Revenue Next Year
- COLL $3.98
- NMM $7.93
- P/E Ratio
- COLL $23.59
- NMM $3.38
- Revenue Growth
- COLL 17.17
- NMM 0.28
- 52 Week Low
- COLL $23.23
- NMM $28.37
- 52 Week High
- COLL $42.29
- NMM $65.89
- Technical
- Relative Strength Index (RSI)
- COLL 55.25
- NMM 43.84
- Support Level
- COLL $29.11
- NMM $39.87
- Resistance Level
- COLL $30.30
- NMM $39.41
- Average True Range (ATR)
- COLL 0.71
- NMM 1.25
- MACD
- COLL -0.03
- NMM -0.28
- Stochastic Oscillator
- COLL 44.32
- NMM 0.00
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.